Logo

Rosetta to Expand Sales Territories, Rebrands Lead Cancer Diagnostic

Jun 06, 2013
Premium

Rosetta Genomics this week announced that it plans to expand its US commercial operations from five sales territories to 12 next month.

The company also said that it has rebranded its flagship microRNA-based diagnostic MiRview Mets2, which is designed to identify the source of cancers of unknown primary origin, as the Rosetta Cancer Origin test.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Rosetta Genomics
RNAi
miRNA
Breaking News
The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.